Sun Pharma Managing Director Dilip Shanghvi On Building A U.S. Base: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro.
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over
MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid